Zilretta is a drug owned by Pacira Pharmaceuticals Inc. It is protected by 2 US drug patents filed in 2018 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 04, 2031. Details of Zilretta's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US8828440 | Corticosteroids for the treatment of joint pain |
Aug, 2031
(6 years from now) | Active |
| US9555048 | Corticosteroids for the treatment of joint pain |
Aug, 2031
(6 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Zilretta's patents.
Latest Legal Activities on Zilretta's Patents
Given below is the list of recent legal activities going on the following patents of Zilretta.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 23 Nov, 2022 | US9555048 |
| Change in Power of Attorney (May Include Associate POA) Critical | 22 Jun, 2022 | US9555048 |
| Email Notification Critical | 22 Jun, 2022 | US9555048 |
| Correspondence Address Change Critical | 21 Jun, 2022 | US9555048 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 31 Jul, 2020 | US9555048 |
| Recordation of Patent Grant Mailed Critical | 31 Jan, 2017 | US9555048 |
| Patent Issue Date Used in PTA Calculation Critical | 31 Jan, 2017 | US9555048 |
| Email Notification Critical | 12 Jan, 2017 | US9555048 |
| Issue Notification Mailed Critical | 11 Jan, 2017 | US9555048 |
| Dispatch to FDC | 21 Dec, 2016 | US9555048 |
FDA has granted several exclusivities to Zilretta. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Zilretta, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Zilretta.
Exclusivity Information
Zilretta holds 1 exclusivities. All of its exclusivities have expired in 2020. Details of Zilretta's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 06, 2020 |
US patents provide insights into the exclusivity only within the United States, but Zilretta is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Zilretta's family patents as well as insights into ongoing legal events on those patents.
Zilretta's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Zilretta's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Aug 04, 2031 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Zilretta Generic API suppliers:
Triamcinolone Acetonide is the generic name for the brand Zilretta. 46 different companies have already filed for the generic of Zilretta, with Astellas having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Zilretta's generic
Alternative Brands for Zilretta
Zilretta which is used for managing pain or inflammation through injectable controlled release of triamcinolone acetonide., has several other brand drugs using the same active ingredient (Triamcinolone Acetonide). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Bausch And Lomb Inc |
| |
| Chattem Sanofi |
| |
| Harrow Eye |
| |
| Sanofi Aventis Us |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Triamcinolone Acetonide, Zilretta's active ingredient. Check the complete list of approved generic manufacturers for Zilretta
About Zilretta
Zilretta is a drug owned by Pacira Pharmaceuticals Inc. It is used for managing pain or inflammation through injectable controlled release of triamcinolone acetonide. Zilretta uses Triamcinolone Acetonide as an active ingredient. Zilretta was launched by Pacira Pharms Inc in 2017.
Approval Date:
Zilretta was approved by FDA for market use on 06 October, 2017.
Active Ingredient:
Zilretta uses Triamcinolone Acetonide as the active ingredient. Check out other Drugs and Companies using Triamcinolone Acetonide ingredient
Treatment:
Zilretta is used for managing pain or inflammation through injectable controlled release of triamcinolone acetonide.
Dosage:
Zilretta is available in for suspension, extended release form for intra-articular use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 32MG/VIAL | FOR SUSPENSION, EXTENDED RELEASE | Prescription | INTRA-ARTICULAR |